Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
June 21 2021 - 8:05AM
Business Wire
Company to discuss clinical progress of
Trappsol® Cyclo™ development program for the treatment of
Niemann-Pick Disease Type C (NPC)
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
the “Company”), a clinical stage biotechnology company dedicated to
developing life-changing medicines through science and innovation
for patients and families living with diseases, today announced it
will present at the 2021 NPC Conference hosted by the Australian
NPC Disease Foundation being held virtually June 25-26, 2021.
The Cyclo Therapeutics session will be held Friday, June 25,
2021, 11 AM – 12 PM AEST / Thursday, June 24, 2021, 9 PM – 10 PM
EDT. During the session, Cyclo Therapeutics will discuss its
proprietary formulation of hydroxypropyl beta cyclodextrin,
Trappsol® Cyclo™, delivered intravenously, and the progress of its
clinical development program for the treatment of NPC. Details of
the Company’s presentation are as follows:
Title:
Results from Phase 1 Study to Evaluate the
Single- and Multiple-Dose Pharmacokinetics of Intravenous Trappsol®
Cyclo™ in Patients with Niemann-Pick Disease Type C (NPC-1) and the
Effects of Dosing upon Biomarkers of NPC Disease
Presenter:
Caroline Hastings, MD, Director, Pediatric
Hematology Oncology Fellowship Program, Children's Hospital &
Research Center Oakland and Professor of Pediatrics, University of
California, San Francisco, School of Medicine
Title:
Top Line Results from Phase 1/2 Study to
Evaluate Safety and Efficacy of Intravenous Trappsol® Cyclo™ in
Patients with Niemann-Pick Disease Type C1
Presenter:
Julian AJ Raiman MBBS MSc MRCP, Consultant
Inherited Metabolic Disease, Birmingham Children's Hospital,
Birmingham, UK
Title:
Phase 3 Study (TransportNPC) to Evaluate
Intravenous Trappsol® Cyclo™ in Pediatric and Adult Patients with
Niemann-Pick Disease Type C1
Presenter:
Gerald Cox, MD PhD, Acting Chief Medical
Officer, Cyclo Therapeutics, Inc.
A live webcast of the presentation will be available to
registered attendees. The presentations will also be made available
on the Presentations page in the Investors section of the Company’s
website. For more information about the event, please visit:
www.npcd.org.au/npcconf2021.
Cyclo Therapeutics recently announced the commencement of its
pivotal Phase 3 study (“TransportNPC”) evaluating Trappsol® Cyclo™
for the treatment of NPC. The TransportNPC study has the regulatory
and IRB approval required to commence patient enrollment, and site
activation is underway. For more information about the TransportNPC
study, visit www.ClinicalTrials.gov and reference identifier
NCT04860960.
Cyclo Therapeutics has received Orphan Drug Designation for
Trappsol® Cyclo™ to treat NPC in both the US and EU, and
additionally, Fast Track and Rare Pediatric Disease Designations in
the US. The Rare Pediatric Disease Designation is one of the chief
requirements for sponsors to receive a Priority Review Voucher in
the US upon marketing authorization.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology
company dedicated to developing life-changing medicines through
science and innovation for patients and families suffering from
disease. The Company’s Trappsol® Cyclo™, an orphan drug designated
product in the United States and Europe, is the subject of three
ongoing formal clinical trials for Niemann-Pick Disease Type C, a
rare and fatal genetic disease, (www.ClinicalTrials.gov
NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company
is planning an early phase clinical trial using Trappsol® Cyclo™
intravenously in Alzheimer’s Disease based on encouraging data from
an Expanded Access program for late-onset Alzheimer’s Disease
(NCT03624842). Additional indications for the active ingredient in
Trappsol® Cyclo™ are in development. For additional information,
visit the Company’s website: www.cyclotherapeutics.com.
Safe Harbor Statement
This press release contains “forward-looking statements” about
the company’s current expectations about future results,
performance, prospects and opportunities, including, without
limitation, statements regarding the satisfaction of closing
conditions relating to the offering and the anticipated use of
proceeds from the offering. Statements that are not historical
facts, such as “anticipates,” “believes” and “expects” or similar
expressions, are forward-looking statements. These statements are
subject to a number of risks, uncertainties and other factors that
could cause actual results in future periods to differ materially
from what is expressed in, or implied by, these statements. The
factors which may influence the company’s future performance
include the company’s ability to obtain additional capital to
expand operations as planned, success in achieving regulatory
approval for clinical protocols, enrollment of adequate numbers of
patients in clinical trials, unforeseen difficulties in showing
efficacy of the company’s biopharmaceutical products, success in
attracting additional customers and profitable contracts, and
regulatory risks associated with producing pharmaceutical grade and
food products. These and other risk factors are described from time
to time in the company’s filings with the Securities and Exchange
Commission, including, but not limited to, the company’s reports on
Forms 10-K and 10-Q. Unless required by law, the company assumes no
obligation to update or revise any forward-looking statements as a
result of new information or future events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210621005110/en/
JTC Team, LLC Jenene Thomas (833) 475-8247 CYTH@jtcir.com
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Sep 2023 to Sep 2024